Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults
Learn more about:
Related Clinical Trial
Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Study
A Study to Evaluate a PIKA-Adjuvanted Inactivated Rabies Vaccine
Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
Survey of Human Rabies Immune Globulin Safety in Children
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
Immunity Persistence After Abridged Intradermal Rabies PEP
A Phase III Clinical Study to Evaluate SYN023’s Efficacy and Safety
Immunogenicity and Safety of Verorab® in a “One-week” Intradermal Post-exposure Prophylaxis Regimen
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)
Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.
Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
Immunogenicity and Safety of Verorab™ in Indian Population
A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects
Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination
The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans
A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac’s Candidate Rabies mRNA Vaccine in Healthy Adults
A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects
Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
RNActive® Rabies Vaccine (CV7201) in Healthy Adults
Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients
Rabies Immunization Concomitant With JEV in Children
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)
Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose
Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults
Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly
A Phase Ib Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
Rabies Immune Plasma Booster Study
Immune Response After Booster Vaccination in HIV – Infected Patients Who Received Rabies Primary Vaccination
Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen
Simplifying the Rabies Pre-exposure Vaccination
Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response
Improving Adherence to Rabies PEP Guideline Recommendations
Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant
Study of the Purified Vero Rabies Vaccine – Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
Immunological Tolerance After Frequent Rabies Booster Vaccinations
Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults